Gangliosides: Treatment Avenues in Neurodegenerative Disease.

Pharmacology, Toxicology and Pharmaceutical Science

• Degenerative Disease 100%
• Ganglioside 100%
• Huntington Chorea 80%
• Placebo 60%
• Head Injury 40%
• Diseases 20%
• Replacement Therapy 20%
• Amyloid 20%
• Alzheimer Disease 20%
• Disease Model 20%
• Diabetes Mellitus 20%
• Parkinson Disease 20%
• Injury 20%
• Mitogen Activated Protein Kinase 3 20%
• Subarachnoid Hemorrhage 20%
• Spinal Cord Injury 20%
• Ganglioside GM1 20%
• Symptom 20%

Neuroscience

• Ganglioside 100%
• Huntington's Disease 80%
• Randomized Controlled Trial 60%
• Placebo 60%
• In Vivo 20%
• Central Nervous System 20%
• Parkinson's Disease 20%
• Endoplasmic reticulum 20%
• Subarachnoid Hemorrhage 20%
• Spinal Cord Injury 20%
• Alzheimer's Disease 20%
• In Vitro 20%
• Cell Membrane 20%
• Amyloid 20%
• Mitogen Activated Protein Kinase 3 20%
• Ganglioside GM1 20%
• Membrane Component 20%

Keyphrases

• Gangliosides 100%
• Placebo 60%
• Randomized Controlled Trial 60%
• BSE Crisis 20%
• Spinal Cord Compression 20%
• Consciousness Disturbance 20%
• Motor Symptoms 20%
• Craniocerebral Injury 20%
• Symptom Progression 20%
• Clinical Experience 20%
• GM1 Ganglioside 20%
• Closed Head Injury 20%
• Chronic Spinal Cord Injury 20%
• Stroke Treatment 20%
• Behavioral Level 20%
• Pathological Phenotype 20%